Imagion Biosystems Receives FDA Clearance for HER2-Targeted MRI Imaging Agent Trial
核心洞察
Imagion Biosystems (搜索) received FDA IND clearance for its MagSense HER2 (搜索) imaging agent, enabling a Phase 1b/2 trial in HER2-positive breast cancer (搜索) patients.
The trial targets approximately 450,000 women diagnosed globally with HER2-positive breast cancer (搜索) annually, focusing on improving lymph node staging accuracy.
Patient recruitment is scheduled to begin in Q3 2026, with the 18-24 month trial designed in three sequential parts providing multiple interim readouts.
Imagion Biosystems (搜索) has achieved a significant regulatory milestone with the US FDA issuing a Study May Proceed Notice for its MagSense HER2 (搜索) Imaging Agent under IND number 165081. The clearance allows the company to proceed with a Phase 1b/2 trial in HER2-positive breast cancer (搜索) patients, marking the transition from preclinical development to human testing after nearly nine years of development.
Trial Design and Timeline
The upcoming Phase 1b/2 trial is structured in three sequential parts designed to provide multiple data readouts over an 18-24 month period. Part A will collect additional safety data on an initial patient cohort, Part B will test an optimized dose and imaging protocol, and Part C will establish diagnostic performance in a larger patient group. Patient recruitment is targeted for the third quarter of 2026, with site contracting already underway under the leadership of principal investigator Dr. Eghtedari at City of Hope (搜索) in Los Angeles.
MagSense Technology Platform
MagSense represents a targeted MRI imaging agent that utilizes iron oxide nanoparticles attached to antibodies that bind specifically to cancer cells. This approach enables tumors to appear more sharply on MRI scans compared to conventional imaging methods. The technology aims to provide both the tissue detail of MRI and the molecular precision of targeted agents without requiring ionizing radiation.
Previous Phase 1 study results demonstrated that independent radiologists could visually distinguish between cancer-involved lymph nodes and healthy tissue. The current Phase 1b/2 trial is designed to transform this visual signal into measurable, dose-optimized diagnostic performance with statistical validation.
Market Opportunity and Clinical Need
The trial targets HER2-positive breast cancer (搜索), which affects approximately 450,000 women globally each year. This aggressive cancer subtype exhibits higher recurrence and metastasis rates, making accurate staging of lymph node involvement critical for treatment decisions. Current nodal assessment relies primarily on ultrasound imaging, which offers convenience and cost-effectiveness but produces variable sensitivity and specificity results.
MagSense is positioned to address the gap between ultrasound's limitations and MRI's superior accuracy by adding molecular targeting capabilities. The technology offers a non-radioactive, MRI-compatible alternative that could improve diagnostic certainty in this aggressive cancer subtype.
Regulatory and Development Progress
The FDA's IND clearance followed comprehensive review of preclinical data, manufacturing controls, quality systems, and trial protocols. Imagion submitted its first Investigational New Drug application in January 2026, with initial administrative questions from the regulator already addressed. The company has indicated that trial initiation could potentially begin as early as June 2026.
The company underwent restructuring in early 2025 to reduce its cost base while advancing the MagSense platform. The technology's potential advantages, combined with MRI's larger global footprint compared to PET imaging, position the company for potential strategic partnering opportunities with larger imaging companies.